Abstract

A series of experiments examined the effects of the cannabinoid CB 1 receptor agonist CP 55,940 ((−)- cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]- trans-4-(3-hydroxypropyl)cyclohexanol) on the motivation to consume beer, near-beer (a beer-like beverage containing <0.5% ethanol) and sucrose solutions in rats. The experiments employed a `lick-based progressive ratio paradigm' in which an ever increasing number of licks had to be emitted at a tube for each successive fixed unit of beverage delivered. Break point, the lick requirement at which responding ceased, was used as an index of motivation. In the first experiment, CP 55,940 (10, 30 or 50 μg/kg) caused a dose-dependent increase in break points for beer (containing 4.5% ethanol v/v) and for near-beer. The highest (50 μg/kg) dose of CP 55,940 also significantly decreased locomotor activity. In the second experiment, CP 55,940 (10 or 30 μg/kg) dose-dependently increased break points in rats licking for `light' beer (containing 2.7% ethanol v/v) or for a sucrose solution (8.6% w/v) containing the same number of calories as the beer. In the third experiment, the facilitatory effects of CP 55,940 (30 μg/kg) on responding for beer and near-beer were reversed by both the cannabinoid CB 1 receptor antagonist SR 141716 ( N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1 H-pyrazole-3-carboxamide hydrochloride) (1.5 mg/kg) and the opioid receptor antagonist naloxone (2.5 mg/kg). Naloxone had a proportionally greater effect on rats licking for beer compared to near-beer, consistent with previous reports of opioid receptor mediation of alcohol craving. These results show that cannabinoids modulate the motivation for beer via both cannabinoid CB 1 receptors and opioid receptors. The similar effect of CP 55,940 on the motivation for beer, near-beer and sucrose suggests that the drug effect may reflect a general stimulatory effect on appetite for palatable beverages, although a more specific effect on the desire for alcohol cannot be ruled out.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.